Effects of alendronate on gastric and duodenal mucosa

American Journal of Gastroenterology

Volumn 93, Issue 5, 1998, Pages 753-757

  Lanza, Frank ^a   Rack, Mary Frances ^b   Simon, Thomas J ^b   Lombardi, Antonio ^b   Reyes, Robert ^b   Suryawanshi, Shailaja ^b  

^a Houston Institute for Clinical Research   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DUODENUM INJURY; FEMALE; GASTROSCOPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PARALLEL DESIGN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EROSION;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOUBLE-BLIND METHOD; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED;

EID: 0032080996     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.219_a.x     Document Type: Article

References (15)

1. 1. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
2. 2. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-50.
3. 3. Eisman JA, Christiansen C, McClung M, et al. Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. J Bone Miner Res 1995;10(suppl 1):S176 (abstract).
4. 4. Yates AJ, McClung M, Ravn P, et al. Epic: A 1,609-subject osteoporosis prevention study. J Bone Miner Res 1995;10(suppl 1):S254 (abstract).
5. 5. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
6. 6. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate: A meta-analysis. JAMA 1997;227:1159-64.
7. 7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
8. 8. Graham DY, Malaty HM, Goodgame R. Alendronate causes gastric mucosal damage similar to NSAIDS [Abstract]. 61st Annual Scientific Meeting of the American College of Gastroenterology; Oct 21-23, 1996.
9. 9. Lanza FL, Peace K, Gustitus L, et al. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 1988;83:143-6.
10. 10. Lanza FL, Graham DY, Davis RE, et al. Endoscopic comparison of cimetidine and sucralfate for the prevention of naproxen-induced acute gastroduodenal injury; effect of scoring method. Dig Dis Sci 1990;35: 1494-9.
11. 11. Klotz JH. The Wilcoxon, ties and the computer. JASA 1966;61:772-87.
12. 12. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. New Engl J Med 1996;335:1016-21.
13. 13. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989;24(suppl 163):24-31.
14. 14. Tucci JR, Tonino RT, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
15. 15. Lanza FL. The effects of amino-versus alkyl-bisphosphonates on the healing of aspirin-induced stomach erosions in healthy subjects. Am College of Gastroenterology; 61st Annual Scientific Meeting; October 21-23, 1996, Abs. 133.